- Home
- MANH vs EXAS Comparison
MANH vs EXAS Comparison
Compare MANH & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MANH
- EXAS
- Stock Information
- Founded
- MANH 1990
- EXAS 1995
- Country
- MANH United States
- EXAS United States
- Employees
- MANH N/A
- EXAS N/A
- Industry
- MANH Computer Software: Prepackaged Software
- EXAS Medical Specialities
- Sector
- MANH Technology
- EXAS Health Care
- Exchange
- MANH Nasdaq
- EXAS Nasdaq
- Market Cap
- MANH 13.0B
- EXAS 11.0B
- IPO Year
- MANH 1998
- EXAS N/A
- Fundamental
- Price
- MANH $181.42
- EXAS $66.98
- Analyst Decision
- MANH Buy
- EXAS Strong Buy
- Analyst Count
- MANH 12
- EXAS 20
- Target Price
- MANH $222.18
- EXAS $68.20
- AVG Volume (30 Days)
- MANH 658.8K
- EXAS 2.3M
- Earning Date
- MANH 10-21-2025
- EXAS 11-03-2025
- Dividend Yield
- MANH N/A
- EXAS N/A
- EPS Growth
- MANH 0.28
- EXAS N/A
- EPS
- MANH 3.52
- EXAS N/A
- Revenue
- MANH $1,066,804,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- MANH $5.24
- EXAS $16.68
- Revenue Next Year
- MANH $7.02
- EXAS $12.36
- P/E Ratio
- MANH $51.61
- EXAS N/A
- Revenue Growth
- MANH 4.10
- EXAS 12.55
- 52 Week Low
- MANH $140.81
- EXAS $38.81
- 52 Week High
- MANH $312.60
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- MANH 34.23
- EXAS 77.44
- Support Level
- MANH $175.23
- EXAS $62.39
- Resistance Level
- MANH $183.39
- EXAS $65.44
- Average True Range (ATR)
- MANH 7.35
- EXAS 1.67
- MACD
- MANH -1.37
- EXAS -0.02
- Stochastic Oscillator
- MANH 20.90
- EXAS 95.16
About MANH Manhattan Associates Inc.
Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers around the world.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.